<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Savara Inc — News on 6ix</title>
    <link>https://6ix.com/company/savara-inc</link>
    <description>Latest news and press releases for Savara Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 15 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/savara-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c60378dffbe2df11ad98.webp</url>
      <title>Savara Inc</title>
      <link>https://6ix.com/company/savara-inc</link>
    </image>
    <item>
      <title>Savara Announces the U.S. Food &amp; Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)</title>
      <link>https://6ix.com/company/savara-inc/news/savara-announces-the-us-food-and-drug-administration-fda-has-extended-the-review-period-for-the-molgramostim-inhalation-solution-molgramostim-biologics-license-application-bla-in-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-announces-the-us-food-and-drug-administration-fda-has-extended-the-review-period-for-the-molgramostim-inhalation-solution-molgramostim-biologics-license-application-bla-in-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap</guid>
      <pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
      <description>-- Prescription Drug User Fee Act (PDUFA) Target Action Date Extended by Three Months to November 22, 2026 -- LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc.</description>
    </item>
    <item>
      <title>Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference</title>
      <link>https://6ix.com/company/savara-inc/news/savara-to-present-new-data-at-the-american-thoracic-society-ats-2026-international-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-to-present-new-data-at-the-american-thoracic-society-ats-2026-international-conference</guid>
      <pubDate>Tue, 14 Apr 2026 12:05:00 GMT</pubDate>
      <description>LANGHORNE, Pa., April 14, 2026--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations at the ATS International Conference in Orlando, Florida, May 17-20, 2026.</description>
    </item>
    <item>
      <title>Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)</title>
      <link>https://6ix.com/company/savara-inc/news/savara-announces-the-uk-medicines-and-healthcare-products-regulatory-agency-mhra-has-accepted-the-molbreevi-marketing-authorisation-application-maa-for-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-announces-the-uk-medicines-and-healthcare-products-regulatory-agency-mhra-has-accepted-the-molbreevi-marketing-authorisation-application-maa-for-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap</guid>
      <pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
      <description>-- MHRA’s Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug</description>
    </item>
    <item>
      <title>Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)</title>
      <link>https://6ix.com/company/savara-inc/news/savara-announces-european-medicines-agency-ema-validation-of-marketing-authorization-application-maa-for-molbreevi-in-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-announces-european-medicines-agency-ema-validation-of-marketing-authorization-application-maa-for-molbreevi-in-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap</guid>
      <pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
      <description>-- EMA Review of MOLBREEVI MAA Has Now Initiated, Decision Expected in Q1 2027 -- -- MOLBREEVI Biologics License Application (BLA) is Currently Under</description>
    </item>
    <item>
      <title>Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/savara-inc/news/savara-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update</guid>
      <pubDate>Fri, 13 Mar 2026 12:05:00 GMT</pubDate>
      <description>LANGHORNE, Pa., March 13, 2026--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business update.</description>
    </item>
    <item>
      <title>Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)</title>
      <link>https://6ix.com/company/savara-inc/news/savara-provides-regulatory-update-on-the-molbreevi-development-program-in-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap-7</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-provides-regulatory-update-on-the-molbreevi-development-program-in-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap-7</guid>
      <pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
      <description>-- Day 74 Letter Received from the U.S. Food and Drug Administration (FDA) Indicated the Agency Has No Plans to Convene an Advisory Committee -- -- Company</description>
    </item>
    <item>
      <title>Savara Announces Participation in 2026 Citizens Life Sciences Conference</title>
      <link>https://6ix.com/company/savara-inc/news/savara-announces-participation-in-2026-citizens-life-sciences-conference-119</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-announces-participation-in-2026-citizens-life-sciences-conference-119</guid>
      <pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
      <description>LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory</description>
    </item>
    <item>
      <title>Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)</title>
      <link>https://6ix.com/company/savara-inc/news/savara-announces-the-us-food-and-drug-administration-fda-filed-the-molbreevi-biologics-license-application-bla-in-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-announces-the-us-food-and-drug-administration-fda-filed-the-molbreevi-biologics-license-application-bla-in-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap</guid>
      <pubDate>Fri, 20 Feb 2026 21:15:00 GMT</pubDate>
      <description>LANGHORNE, Pa., February 20, 2026--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced the FDA has filed for review the BLA for MOLBREEVI as a therapy to treat patients with autoimmune PAP. The FDA granted Priority Review with a PDUFA action date of August 22, 2026.</description>
    </item>
    <item>
      <title>Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*</title>
      <link>https://6ix.com/company/savara-inc/news/savara-announces-amendment-hercules-capital-debt-facility-providing-75m-additional</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-announces-amendment-hercules-capital-debt-facility-providing-75m-additional</guid>
      <pubDate>Tue, 27 Jan 2026 05:00:00 GMT</pubDate>
      <description>-- When Combined with Recently Announced $75M Royalty Financing, the Company Will Have Access to ~$150M of Non-Dilutive Capital for Launch of MOLBREEVI --</description>
    </item>
    <item>
      <title>Savara Announces New Employment Inducement Grant</title>
      <link>https://6ix.com/company/savara-inc/news/savara-announces-employment-inducement-grant-210500733</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-announces-employment-inducement-grant-210500733</guid>
      <pubDate>Fri, 16 Jan 2026 21:05:00 GMT</pubDate>
      <description>LANGHORNE, Pa., January 16, 2026--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.</description>
    </item>
    <item>
      <title>PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*</title>
      <link>https://6ix.com/company/savara-inc/news/pantherx-rare-selected-savara-u-210500471</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/pantherx-rare-selected-savara-u-210500471</guid>
      <pubDate>Thu, 08 Jan 2026 21:05:00 GMT</pubDate>
      <description>LANGHORNE, Pa., January 08, 2026--PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, and Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced an exclusive distribution agreement for MOLBREEVI. Savara submitted the MOLBREEVI BLA to the U.S. Food and Drug Administration (FDA) in December 2025 for the treatment of autoimmune PAP. Priority Review was req</description>
    </item>
    <item>
      <title>Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)</title>
      <link>https://6ix.com/company/savara-inc/news/savara-resubmits-biologics-license-application-bla-us-food-and-drug-administration</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-resubmits-biologics-license-application-bla-us-food-and-drug-administration</guid>
      <pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
      <description>-- The BLA was Resubmitted with FUJIFILM Biotechnologies (Fujifilm) as the Drug Substance Manufacturer and Priority Review was Requested -- LANGHORNE,</description>
    </item>
    <item>
      <title>Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/savara-inc/news/savara-announces-participation-44th-annual-jp-morgan-healthcare-conference-2025-12-17</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-announces-participation-44th-annual-jp-morgan-healthcare-conference-2025-12-17</guid>
      <pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
      <description>LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory</description>
    </item>
    <item>
      <title>Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*</title>
      <link>https://6ix.com/company/savara-inc/news/savara-announces-european-patent-office-epo-intends-grant-patent-liquid-formulation</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-announces-european-patent-office-epo-intends-grant-patent-liquid-formulation</guid>
      <pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
      <description>-- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 -- -- Savara Was Also Recently Granted a European Patent</description>
    </item>
    <item>
      <title>Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System</title>
      <link>https://6ix.com/company/savara-inc/news/savara-and-pari-granted-european-patent-covering-drug-device-combination-molbreevi</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-and-pari-granted-european-patent-covering-drug-device-combination-molbreevi</guid>
      <pubDate>Tue, 02 Dec 2025 05:00:00 GMT</pubDate>
      <description>LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases,</description>
    </item>
    <item>
      <title>Savara Announces Participation in Upcoming Investor Healthcare Conferences</title>
      <link>https://6ix.com/company/savara-inc/news/savara-announces-participation-upcoming-investor-healthcare-conferences-2025-11-20</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-announces-participation-upcoming-investor-healthcare-conferences-2025-11-20</guid>
      <pubDate>Thu, 20 Nov 2025 05:00:00 GMT</pubDate>
      <description>LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory</description>
    </item>
    <item>
      <title>Savara Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/savara-inc/news/savara-reports-third-quarter-2025-financial-results-and-provides-business-update-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-reports-third-quarter-2025-financial-results-and-provides-business-update-2025</guid>
      <pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
      <description>-- On Track to Resubmit the Biologics License Application (BLA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) in December and</description>
    </item>
    <item>
      <title>Savara Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M</title>
      <link>https://6ix.com/company/savara-inc/news/savara-announces-closing-public-offering-and-full-exercise-underwriters-option</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-announces-closing-public-offering-and-full-exercise-underwriters-option</guid>
      <pubDate>Fri, 31 Oct 2025 04:00:00 GMT</pubDate>
      <description>LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today</description>
    </item>
    <item>
      <title>Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants</title>
      <link>https://6ix.com/company/savara-inc/news/savara-announces-pricing-1300-million-public-offering-common-stock-and-pre-funded</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-announces-pricing-1300-million-public-offering-common-stock-and-pre-funded</guid>
      <pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
      <description>LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today</description>
    </item>
    <item>
      <title>Savara Announces Proposed Public Offering</title>
      <link>https://6ix.com/company/savara-inc/news/savara-announces-proposed-public-offering-2025-10-29</link>
      <guid isPermaLink="true">https://6ix.com/company/savara-inc/news/savara-announces-proposed-public-offering-2025-10-29</guid>
      <pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
      <description>LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases,</description>
    </item>
  </channel>
</rss>